EPO and anemia: In MF patients, disease-related anemia can be exacerbated by treatment with ruxolitinib because of myelosuppression, an adverse event that is consistent with the drug’s interference with erythropoietin signaling via JAK-STAT (especially JAK2), which is essential for erythropoiesis [5].